Transcend Capital Advisors LLC Has $8.62 Million Stock Position in Eli Lilly and Company (NYSE:LLY)

Transcend Capital Advisors LLC lifted its stake in Eli Lilly and Company (NYSE:LLY) by 2.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 14,781 shares of the company’s stock after acquiring an additional 336 shares during the period. Eli Lilly and Company makes up 0.8% of Transcend Capital Advisors LLC’s portfolio, making the stock its 26th largest holding. Transcend Capital Advisors LLC’s holdings in Eli Lilly and Company were worth $8,616,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the business. Lipe & Dalton acquired a new stake in shares of Eli Lilly and Company in the 4th quarter valued at $26,000. Thompson Investment Management Inc. acquired a new position in Eli Lilly and Company during the 3rd quarter valued at about $27,000. Legacy Financial Group LLC bought a new stake in shares of Eli Lilly and Company in the 3rd quarter valued at about $35,000. Optiver Holding B.V. bought a new stake in shares of Eli Lilly and Company in the 3rd quarter valued at about $36,000. Finally, Family CFO Inc bought a new stake in shares of Eli Lilly and Company in the 3rd quarter valued at about $40,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Insider Buying and Selling

In related news, major shareholder Lilly Endowment Inc sold 54,032 shares of the firm’s stock in a transaction on Monday, January 29th. The stock was sold at an average price of $645.07, for a total value of $34,854,422.24. Following the transaction, the insider now owns 99,488,598 shares in the company, valued at $64,177,109,911.86. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.13% of the stock is owned by company insiders.

Eli Lilly and Company Stock Up 1.2 %

Shares of NYSE LLY traded up $8.64 during trading hours on Friday, hitting $733.51. The company had a trading volume of 2,009,249 shares, compared to its average volume of 2,265,427. The stock has a market capitalization of $696.95 billion, a P/E ratio of 126.47, a price-to-earnings-growth ratio of 1.58 and a beta of 0.34. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69. Eli Lilly and Company has a 1-year low of $380.77 and a 1-year high of $800.78. The firm’s 50 day moving average is $761.79 and its 200-day moving average is $666.06.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, topping analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The company had revenue of $9.35 billion during the quarter, compared to the consensus estimate of $8.95 billion. During the same quarter last year, the firm earned $2.09 earnings per share. The company’s revenue was up 28.1% on a year-over-year basis. On average, analysts expect that Eli Lilly and Company will post 12.51 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently issued reports on LLY shares. DZ Bank cut Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 target price for the company. in a research note on Wednesday, February 21st. TheStreet raised Eli Lilly and Company from a “c+” rating to a “b” rating in a research note on Friday, March 8th. Truist Financial reissued a “buy” rating and set a $850.00 target price on shares of Eli Lilly and Company in a research note on Friday, March 22nd. Barclays increased their target price on Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 7th. Finally, Wells Fargo & Company increased their target price on Eli Lilly and Company from $700.00 to $825.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 6th. Three equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $728.05.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.